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ABSTRACT 
 
 
Indirubin is the active ingredient in the ancient herbal remedy, Danggui 
Longhui Wan, which is used as an anti-leukemic, anti-inflammatory, and 
detoxification treatment. Indirubin-3’-monoxime (IO) is the most widely studied of 
the indirubin derivatives. Most have been shown to inhibit cyclin-dependent 
kinases and glycogen synthase kinases, triggering cell cycle arrest and apoptosis 
with different levels of activity depending on the particular structure.  These 
kinases inhibited by indirubin(s) play key roles in cellular proliferation and 
immune functions, therefore synthetic indirubins may have significant 
applications as therapeutic agents for cancer, inflammation, and neurological 
diseases.  
  Indirubin is also a potent aryl hydrocarbon receptor (AhR) agonist. The 
AhR is a cytosolic protein, which upon ligand binding is translocated to the 
nucleus and acts as a transcription factor for genes involved in drug metabolism, 
oxidative stress, and inhibitors of the cell cycle.  Known anthropogenic ligands 
(PCBs, dioxins, PAHs etc.) are mutagenic, carcinogenic, and immunotoxic.  In 
this study, I examined the effects of select indirubins on gene/protein expression 
profiles, AhR activation, and cellular functions in the mouse macrophage cell line 
RAW 264.7.  Structure activity relationships (SAR) show that different derivatives 
of indirubin may differentially affect AhR activation, kinase inhibition, and/or other 
cellular functions, including intracellular killing of bacteria. The ultimate goal was 
to identify a synthetic indirubin derivative that would be beneficial to cancer and 
inflammation research without being overtly toxic. 
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From this research, Indirubin-3’-(2,3 dihydroxypropyl)-oximether) (E804), 
and 6-bromoindirubin-3-monoxime (BIO) were shown to be very potent AhR 
ligands with strong anti-inflammatory properties. This study also shows that E804 
has more clinical promise than its more famous counterpart indirubin-3’-
monoxime. 
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LITERATURE REVIEW 
 
The Institute of Hematology, Chinese Academy of Sciences (1976) treated 
16 chronic myelogenous leukemia (CML) patients with ingredients from an 
ancient medicinal recipe called Danggui Longhui Wan (DLW), and reported that 4 
patients showed complete remission and 5 partial remission. The ancient remedy 
is made from extracts of several indigo-producing plants including Polygonum 
tinctorium, Isatis indigotica and Isatis tinctoria. According to the Chinese 
Academy of Medical Sciences (1975), I. tinctoria extracts significantly prolonged 
the life span of rats with Walker carcinosarcoma 256 tumors, whereas other plant 
extracts from DLW did not. The anti-leukemic properties from DLW were found to 
come from the ingredient Qing Dai which is made up of indirubin, an isomer of 
indigo. Indirubin is a red colored bis-indole metabolite of tryptophan found in 
indigo-producing plants (Wu et al., 1979). In a later clinical trial, 253 patients with 
CML were given 150-200mg/day of indirubin synthesized from indigo blue. Over 
60% of the patients showed at least partial remission (Reviewed in Xiao et al., 
2002). Although these findings were exciting, due to indirubin’s poor solubility 
patients had severe gastrointestinal side-effects and were forced to stop 
treatment (Zheng et al., 1979). Recently, several derivatives have been 
synthesized to increase the efficacy of the compound and decrease the toxicity 
side effects of indirubin.  
The mechanisms of action which indirubin and its derivatives possess are 
not well known. The 11 herb remedy, DLW has a broad list of pharmacologically 
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relevant effects that could be exploited. Consumers also use the ancient herbal 
medicine for its detoxification and anti-inflammatory properties in treating chronic 
disease (Kunikata et al 2000). It is prudent to examine nutraceutical remedies not 
only for safety and efficacy but for future drug therapies. One critical aspect for 
this investigation is the effect indirubin has on gene expression, cellular signaling, 
protein function, and inflammation in macrophages. 
Activated macrophages display several important physiological functions 
such as phagocytosis, antigen presentation, and release of a diverse arsenal of 
biological mediators, for example, reactive oxygen intermediates and reactive 
nitrogen species, cytokines, and hydrolytic enzymes (Reviewed in Billack 2006). 
These actions make macrophages vital cells in the immune system, particularly 
in their role in innate immunity. The broad and essential roles these cells play 
make them attractive targets for therapeutic drug treatments. 
 A major aspect of innate immunity is the inflammatory response which 
can be stimulated by diverse chemical, infectious, or mitogenic stimulants. 
Mediators of the immune system include, chemokines, enzymes that promote 
vascular permeability and migration of immunomodulators, chemoattractant 
molecules responsible for the recruitment of neutrophils and monocytes, and the 
inflammatory family of cytokines which include interleukin 1 (IL-1), IL-6, IL-18, 
tumor necrosis factor α (TNF-α), colony stimulating factors (CSF) and many 
others that regulate the duration and potency of the inflammatory response 
(Reviewed in O’Shea et al., 2008; Jones et al., 2000). The innate immune system 
is in close association with the more specific adaptive immune response. IL-18 is 
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one of the cytokines produced during the inflammatory response involved in 
crucial crosstalk in promoting T helper cell 1 response in the adaptive immune 
response (Wuttge et al., 2003). 
Hematopoietic stem cells develop into monocytes in the presence of 
macrophage colony stimulating factor and granulocyte-macrophage colony 
stimulating factor within the bone marrow. Monocytes enter the blood stream and 
migrate to tissues where they differentiate into macrophages. Macrophages are 
activated by the recognition of pathogen associated molecular patterns (PAMPs), 
which are conserved sequences on microbial non-self molecules, by pattern 
recognition receptors like toll like receptors (TLRs). To date there are at least 13 
different TLRs in mammals (Roach et al., 2005) that bind to PAMPs and self-
altered molecules (Akira et al., 2004). Toll-like receptor 4 (TLR4) is a 
transmembrane receptor that recognizes several ligands notably 
lipopolysaccharide (LPS). Ligand (LPS) binding initiates the recruitment of 
various adaptor proteins to the cytosolic Toll-IL-1 receptor (TIR) domain which 
activates a signaling pathway leading to the activation and subsequent nuclear 
translocation of nuclear factor kappa B (NF-кB). The induction of inflammatory 
genes as well as genes that regulate cell cycle progression, apoptosis and cell 
differentiation are expressed depending on the nature and specific manner in 
which ligand binds (Yan et al., 2007). Other toll-like receptors also mediate 
inflammation, for example, TLR1 and TLR2 ligand binding also initiates the 
translocation of NF-κB promoting the gene expression of IL-6 (Krishnan et al., 
2007). 
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The role cytokines play in the immune response has been an area vastly 
studied particularly in inflammation. Interleukins, interferons, and colony-
stimulating factors bind to type I and II cytokine receptors (Boulay et al., 2003) 
that commonly have a cytoplasmic Janus kinase (Jak) family associated with it. 
Specific receptor/cytokine binding activates Jak kinases to phosphorylate 
tyrosine residues in the receptor cytoplasmic domain creating a docking site for 
Src homology 2 domain proteins, like Stat transcription factors (signal 
transducers and activators of transcription). This cascade of cytokine signaling is 
known as the JAK-STAT pathway (Kisseleva, et al., 2002). There are seven 
members of the Stat family of DNA-binding proteins, Stat1, Stat2, Stat3, Stat4, 
Stat5a, Stat5b, and Stat6, which regulate gene expression by the specific 
cytokine bound. A hallmark of acute inflammation is a change in plasma proteins 
called acute phase proteins; IL-6 is the principle cytokine responsible for the 
concentration level change of these proteins (Gauldie et al., 1987).  Agents that 
inhibit IL-6 production show promise in clinical trials of patients with arthritis and 
chronic inflammatory diseases (Crocker et al., 2003). 
In addition to cytokines macrophages produce enzymes that are key 
components in innate immunity that result in the production of nitric oxide, a 
potent player in inflammation. There are three types of nitric oxide synthases, 
NOS1 and NOS3 also known as neuronal NOS (nNOS) and endothelial NOS 
(eNOS) are named for cells they were characterized in. NOS2 better known as 
inducible nitric oxide synthase (iNOS) is not constitutively expressed but 
synthesized upon activation in cells. iNOS acts on the amino acid L-arginine to 
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convert it to L-citrulline and nitric oxide (NO) and released in what is called the L-
arginine-NO pathway (Moncada et al., 1989; Moncada et al., 2002). Regulation 
of iNOS is achieved by cytokines (Liew et al., 1997) and mediating the stability 
and activation of mRNA. Several transcription factors regulate the iNOS gene 
promoter including NF-кB and signal transducer and activator of transcription 1 
(STAT1) (Reviewed in Tripathi et al., 2007). LPS alone is capable of inducing 
Nos2 gene in the mouse macrophage cell line RAW 264.7; however, in most 
other cell lines cytokines and other stimulating factors are needed (MacMicking 
et al., 1997).  Knockout mice deficient of the iNOS gene show greater 
susceptibility to infection and an increase in fatality when they encounter bacteria 
compared to their wild-type controls (MacMicking et al., 1997; MacMicking et al., 
1995). 
Nitric oxide is a toxic free radical gas that is cell permeable and can react 
with molecular oxygen to form reactive nitrogenous intermediates (Eiserich et al., 
1998). These highly reactive species are capable of killing or dramatically 
reducing the replication of microbial agents including viruses, bacteria, and fungi. 
On the contrary, however, the overproduction of NO can lead to necrosis of 
healthy tissue and host toxicity (Laskin et al., 1996). The role of the small NO 
molecule has drastic effects on virtually ever level of the inflammatory response 
including vascular permeability, vasodilatation, leukocyte migration and 
adhesion, and microbe clearance (Guzik et al., 2003). 
Danggui Longhui Wan has been used for centuries in the treatment of 
chronic inflammatory disease, although the means of action remain elusive, it is 
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reasonable to look at the NF-кB signaling pathway, also known as the central 
mediator of the immune response. It is a key transcription factor that when 
stimulated expresses several inflammatory genes.  NF-кB is a member of the Rel 
domain-containing proteins family, consisting of a heterodimer of p50 and p65. It 
is found in the cytoplasm of cells in association with IкB which holds it in its 
inactive form. It has been reported that there are over 150 extracellular means of 
activation of this pathway including numerous pathogens, cytokines, and stress 
stimuli. Only when activated does IкB kinase (IKK) phosphorylate IкB, signaling 
its degradation to the proteosome, thereby disassociating it from its inhibitory 
hold on the heterodimer. This unmasks the translocation factor enabling the p65 
subunit to be phosphorylated this leads to the translocation of NF-kB to the 
nucleus. NF-kB is responsible for the regulation and activation of many diverse 
genes and pathways, including the expression of many immune modulators, 
inflammatory cytokines, stress responses, and cell proliferation and 
differentiation molecules (Li et al 2002). The transcription factor regulates  
antiapoptotic, inflammatory and stress related genes including SURVIVN, Bcl, 
Cox-2, and cell cycle genes cyclin D1 and c-MYC (Sethi et al, 2006). 
Following earlier observations the effects of indirubin-3’monoxime and 
other indirubin derivatives on the function of RAW 264.7 macrophages, and 
consequently the inflammatory response were investigated; focusing on several 
key modulators of the inflammatory response and report the effect that indirubin 
and its soluble derivatives have on this important aspect of immunity. 
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In 1999, Hoessel et al. reported on a finding that would give great insight, 
interest, and understanding into indirubin and its derivatives. They showed the 
co-crystallization structure of indirubins and cyclin-dependent kinases (CDK1 and 
CDk2), key factors in the progression of the cell cycle. This revealed a 
competitive inhibition of the indole compounds with ATP for the catalytic binding 
site of the kinase. Cyclin-dependent kinase inhibitors halt the cell cycle, therefore 
inducing apoptosis, making them excellent candidates for cancer therapy. 
The mammalian cell cycle is composed of four stages; two gap stages G1 
and G2, a DNA synthesis stage S, and mitosis, M. G1 is a critical checkpoint in 
the progression of a cell from the resting G0 phase through to S phase. The cycle 
is under tight control through the degradation and production of regulatory 
molecules creating an oscillating concentration of protein subunits called cyclins 
which function to activate cyclin dependent kinases (CDKs). The heterodimer of 
cyclin/CDK then phosphorylates key proteins, involved in the progression of the 
cycle, activating or inactivating them in a series of orchestrated regulated events 
through the stages of the cell cycle. The Gap1 cyclin, cyclin D, binds to CDK4 
and CDK6 which are involved in the checkpoint regulation of G1 progression into 
the S phase. CDK4 (6)/cyclin D phosphorylates many substrates including the 
retinoblastoma protein (Rb). The phosphorylation of Rb (pRb) releases its 
repression leading to the activation of the E2F family of transcription factors 
which are responsible for the expression of various genes that are involved in cell 
cycle progression (Reviewed in Johnson et al., 1999). The over-expression of 
cyclin D mRNA and/or protein levels is seen in over 50% of breast cancers (Roy 
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et al., 2006). Therefore, finding a high affinity inhibitor of this cyclin subunit could 
be pivotal in the future of breast cancer treatment, as well as other cancers. 
Hoessel et al., (1999) also reported on the kinase selectivity of various 
derivatives acting on several CDK/cyclin complexes. Derivatives have 
preferential binding affinities for specific CDKs or other structurally related 
kinases based on the chemical makeup and confirmation of the derivative. Indigo 
did not show an inhibition for the enzymes tested, furthering the evidence that the 
active anti-leukemic component of Danggui Longhui Wan is indirubin and not 
indigo. Polychronopoulos et al., (2003) tested numerous indirubin derivatives 
against CDK1/cylin B, CDK5/p25, and GSK-3β, showing that the difference in the 
chemical substitutions of indirubin have different affinities to kinases. The 
selectivity is based on the substituted group that is in contact with the CDK-ATP 
catalytic binding pocket.  
Leclrec et al., (2000) also reported that indirubin and some of its soluble 
derivatives are potent inhibitors of glycogen synthase kinase-3β (GSK-3 β) and 
CDK5 by competing with ATP in the active site of the kinase, similar to its 
inhibition on CDK1 and CDK2 as reported by Hoessel et al., (1999). This finding 
is of much interest due to GSK-3 and CDK5’s role in neurological disorders like 
Alzheimer’s disease and bipolar disease. GSKs are responsible for numerous 
distinct physiological pathways including cell cycle progression (Diehl et al., 
1998), WNT signaling pathway (Willert et al., 1998), and inflammation (Woodgett 
et al., 2005). Imahori et al (1997) reported that the two kinases responsible for 
the formation of neurofibrillary tangles (NFT) are GSK-3B and CDK5, which is 
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one of the hallmarks of Alzheimer’s disease. The neurological disease is 
comprised of paired helical filaments from the abnormal hyperphosphorylation of 
Tau protein by the glycogen synthase and cyclin-dependent-5 kinases (Ferrer et 
al., 2005). The ability of a compound to inhibit such phosphorylation could lead to 
promising agents in the fight against Alzheimer’s and other such diseases. 
Another key turning point in the study of indirubin and its derivatives came 
in 2001 (Adachi et al.) from a finding that indirubin purified from human urine has 
the ability to bind to the cytosolic aryl hydrocarbon receptor (AhR). Polygonum 
tinctorium extracts in addition to alleviating inflammation and cancer are also 
used for enhancing detoxification processes, suggesting that this plant contains 
compounds that induce the family of cytochrome P450 enzymes through the aryl 
hydrocarbon receptor AhR. Adachi et al (2001) showed that indirubin is the most 
likely candidate because it is an AhR ligand capable of inducing CYP1A, a phase 
I drug metabolizing enzyme of the P450 family (Kawajiri et al., 2007). Kawanishi 
et al., (2003) showed that using a reporter yeast construct that indirubin is a 
potent AhR ligand. The CYP1A1 gene expression is induced over twelve fold 
compared to DMSO (carrier control) in human U937 macrophages upon 
treatment with indirubin-3’-monoxime (Springs et al., 2006).  
The immunotoxic, homeostatic, and biologic consequences of many 
halogenated aromatic hydrocarbons (HAH), polychlorinated biphenyls (PCB), 
and other xenobiotic pollutants are a direct effect of their interaction with the AhR 
(Hahn, 1998). The AhR is in the basic helix-loop-helix-PER-ARNT-SIM (bHLH-
PAS) superfamily of transcription factors (reviewed in Schmidt et al., 1996). The 
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bHLH family members have two distinct highly conserved domains, the basic-
region involved in DNA binding and the helix loop helix region involved in protein 
interactions. There are two PAS domains that help facilitate the interaction 
between the receptor and Ah receptor nuclear translocator (ARNT) and ligand 
binding (Emma et al., 1992; Coumailleau et al., 1995). The AhR is also known as 
the dioxin receptor for its high affinity to the ligand 2,3,7,8-tetrachlorodibenzo-p-
dioxin (dioxin or TCDD) which achieved notoriety in the 1970's when it was found 
to be a contaminant in the herbicide Agent Orange. TCDD was also used as 
chemical warfare agent during the Vietnam War (Reviewed in Frumkin, 2003). 
 In the inactivated state, the AhR is a cytosolic ligand-activated 
transcription factor found within most tissues and cells. It is associated with heat 
shock protein 90 (HSP-90) homodimer (Chen et al., 1994), a p23 chaperone 
(Cox et al., 2004), and an immunophilin-related protein XAP-2 (Meyer et al., 
1998). Upon ligand binding, the coupled proteins are disassociated and the AhR-
ligand complex is translocated to the nucleus where it binds with AhR nuclear 
translocator (ARNT). The ligand/receptor/ARNT complex binds to xenobiotic 
response element (XRE), a cassette of specific DNA sequences upstream of 
various genes such as drug metabolizing enzymes CYP1A1, glutathione S-
transferase (GST) (Rushmore et al., 1990) and UDP-glucoronsyltransferase 
(UGT) (Iyanagi et al., 1986) increases the transcription rate of these genes. 
(Reviewed in Shimba et al., 2001; Nohara et al., 2005; Nguyen, et al., 2007; 
Marlowe et al., 2005). These phase II enzyme genes associate with the Nrf2 
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gene battery which binds to antioxidant response elements (AREs) encoding 
several enzymes related to oxidative stress (Kohle et al., 2007). 
 The aryl hydrocarbon receptor is classified as an orphan receptor, in that 
a known endogenous ligand has not yet been found. However, recently it was 
discovered that indirubin, found naturally in human urine, binds the AhR and thus 
may be an endogenous ligand for the receptor (Adachi et al., 2001; Spink et al., 
2003, Schnitzer et al., 2005). Knockaert et al., (2004) showed that Io and various 
other derivatives, including methylated indirubins, rapidly translocate the 
cytosolic AhR to the nucleus. This was an interesting finding because the 
substituted methyl group interferes with the molecules ability to bind to the cyclin-
dependent kinase catalytic site, and therefore is not an inhibitor of the kinase. 
This suggests that some of the effects on cytotoxicity and cell cycle arrest are 
independent of CDK inhibition and could be AhR-dependent.  
This is alarming because most anthropogenic compounds that bind to the 
AhR, for example TCDD and PCB-126 are highly mutagenic, immunotoxic, and 
carcinogenic (Hankinson, 1995 and Andersson et al 2002). Aryl hydrocarbon 
receptor ligands can have both antagonistic and agonistic effects on the AhR 
signaling pathway (Nishiumi et al, 2008). Some ligands that bind to the receptor 
could induce apoptosis and therefore cause growth inhibition in some tumors and 
cancer cells while other ligands promote tumorogenesis (Bradshaw et al 2002, 
Damiens et al 2001, and Koliopanos et al 2002). The alteration of this pathway in 
a non-toxic manner could lead to another mechanism in which indirubins could 
arrest the cell cycle and be beneficial pharmacological agents. 
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Although the anti-cancer properties of indirubins, via CDK-inhibition, are 
the subject of increased area of studies, the effects on inflammation and 
detoxification mechanisms are not well established. This dissertation investigates 
the effects of indirubin derivatives, in comparison with PCB-126 a known AhR 
ligand, on gene/protein expression, AhR activation, and cellular function using a 
murine macrophage cell line RAW 264.7.  
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             Indirubin (IR)                                           Indirubin-3’-monoxime (IO) 
 
 
 
 
 
                                     
 
 6-Bromoindirubin-3’-monoxime                    Indirubin-3’-(2, 3 dihydroxypropyl)-                                  
                     (BIO)                                                      oximether (E804)                           
 
 
 
Figure 1. The structure of indirubin and indirubin derivatives. 
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INTRODUCTION 
 
The multibillion dollar Nutraceuticals industry is growing rapidly, especially 
in the use and production of ancient herbal remedies. Some of the most well 
known of these products are oriental supplements and teas which are readily 
consumed by the American public on the marketing promise of anti-cancer, anti-
inflammation, and anti-disease that leads to longevity and health. The public 
lacks an appropriate knowledge of the ingredients, effects, or modes of action of 
these holistic medicines. Many herbal remedies consist of several ingredients 
leading to the activation of different cellular pathways and “healing” capacities. 
Recently there has been a push to isolate the key active compounds and test 
their efficacy and safety. This study presented herein describes the effects of one 
such natural components, on gene expression, cellular signaling and finally on 
select immunologic cellular functions. 
The Chinese Academy of Medicine identified Qing Dai (indigo naturalis) to 
be the active component of Danggui Longhui Wan, an ancient Chinese herbal 
tea used to treat several conditions, including neoplasia, detoxification, and 
chronic inflammation. The ingredients are derived, in part, from the plants 
Polygonum tinctorium (Polygonaceae) and Istasis indigotica (Brassicaceae) (Wu 
et al., 1979). The minor constituent indirubin (IR), an indigo blue isomer, was 
purified from the active Qing Dai substance, and found to be the compound 
responsible for the anti-leukemic properties that the Chinese tea seemed to 
possess. Indirubin, a metabolite of the amino acid tryptophan, has a colorful red 
appearance formed by the spontaneous dimerization of its colorless precursors 
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indoxyl and isatin (reviewed in Hoessel et al., 1999). In some rare cases, patients 
with catheters get purple urine bag syndrome (PUBS), and will produce purple 
colored urine in the urinary bag, this was found to consist of indirubin and indigo 
(Dealler et al., 1988). In patients with PUBS tryptophan is metabolized by graham 
negative bacteria that act to degrade indican into indigo and indirubin producing 
the purple coloration (Vallejo-Manzur, 2005). The exact mechanism in which 
indirubin is formed from tryptophan varies among its natural sources which 
include; indigo producing plants, Tyrian purple-producing mollusks, wild-type and 
recombinant bacterial strains and mammalian urine including human and bovine 
(Maugard et al., 2001; reviewed in Gillam et al., 2000; Meijer et al., Bhushan et 
al., 2000; 2003; Adachi et al., 2001). 
Over the past two decades indirubin has sparked much interest as a 
pharmacological agent, especially in the use in cancer treatment with the finding 
that indirubin arrests the cell cycle by binding to and inhibiting cyclin-dependent 
kinases (Hoessel et a., 1999). Early clinical trials showed great promise in 
treating chronic myelogenous leukemia (CML) as well as granulocytic leukemia. 
In the patients with CML who received indirubin, 26% showed complete 
remission and 33% partial remission (Gan et al., 1985; reviewed in Hoessel et 
al., 1999). However, the compound is poorly soluble and can cause gastro-
intestinal and toxicity problems. In an effort to minimize side effects and increase 
efficacy of the compound, soluble derivatives have been synthesized, most 
notable indirubin-3’-monoxime (IO). IO has been used in many laboratories to 
study the compounds modes of action and potential for various therapeutic 
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medicines in cancer, inflammation, and neurological disorders.  Some of the 
newly synthesized derivatives have similar effects in the body without the 
insolubility side effects associated with indirubin (Marko et al., 2001; Guengerich 
et al., 2004). 
Recently, it was reported that indirubin, found naturally in human urine, 
binds with high affinity to the aryl hydrocarbon receptor (AhR) (Adachi et al., 
2001; Spink et al., 2003, Schnitzer et al., 2005). The fact that indirubin was found 
naturally in mammalian urine gives intrigue to the possibility of an endogenous 
ligand for the AhR. To date the AhR is considered an orphan receptor, in that a 
known endogenous ligand has not been found. Several halogenated aromatic 
hydrocarbon (HAH) and polycyclic aromatic hydrocarbons (PAH) that are 
considered environmental pollutants bind to the AhR. The most potent and 
famous of which is 2,3,7,8-tetrachlorodibenzene-p-dioxin (TCDD or dioxin). 
Binding of aromatic hydrocarbons to the receptor initiates the AhR signaling 
pathway leading to a wide range of toxic and carcinogenic responses (Marlowe 
et al., 2005).  
The AhR is a member of the PER ARNT SIM (PAS) superfamily of 
proteins (Gu et al., 2000). It is found in the cytoplasm of most cells in an 
inactivated state held by chaperone p23 and heat shock proteins (Chen et al., 
1994; Cox et al., 2004). Ligand binding dissociates these proteins from the 
receptor freeing it to translocate the nucleus. Once in the nucleus the ligand/AhR 
forms a heterodimer with aryl hydrocarbon receptor nuclear translocator (ARNT). 
These complexes can then bind to and manipulate the xenobiotic response 
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element of genes, including drug-metabolizing enzymes such as the cytochrome 
P450 family including CYP genes (Hahn, 1998). Knockaert et al., (2004) showed 
that IO and various other derivatives translocate the cytosolic AhR to the 
nucleus. Further, IO has been found to increase the gene expression of CYP1A1 
in U937 human macrophage cell line (Springs et al., 2006) 
Immune suppression, reproductive, and developmental disorders are 
associated with anthropogenic AhR ligand exposure (Holsapple et al., 1996). 
Therefore, it is alarming that these natural compounds could bind and trigger 
such toxic results.  However, in recent years it has become evident that ligands 
of the AhR not only trigger toxicant enzyme activities but independent of and in 
combination with these activation pathways trigger other signal transduction 
pathways as well (Puga et al., 2002). AhR signaling has been shown to regulate 
developmental cues, cell cycle progression, and homeostasis along with 
chemical toxicity (Reviewed in Nguyen et al., 2008). Several studies have shown 
that the AhR has a role in cell cycle regulation, although the mechanisms are not 
well known. Ge et al. (1998) reported on a direct protein-protein interaction 
between the AhR and the retinoblastoma protein (Rb), a critical molecule in the 
cell cycle. In response to ligand binding there is an increase in gene expression 
of p27, a CDK2 inhibitor, halting the cell cycle in G1. The dual mechanism of 
indirubins is shown in Figure 1 (Knockaert et al., 2003). Dependent on the 
chemical makeup and confirmation of the synthesized derivative (Figure 3.) the 
affinity may be greater for AhR binding, cyclin-dependent kinase inhibition, or 
other cellular pathways. A key question for the future of this area of research is to 
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find a molecule with the beneficial pharmacology effects for medicinal drug 
therapy, without the traditional AhR immunotoxicity and mutagenesis. 
Although the adverse effects of anthropogenic compounds have been 
studied, very little is known about the effects endogenous ligands have on the 
function of macrophages or the immune system. Previous work has shown that 
macrophages are susceptible to AhR activation in terms of phagocytic activity 
(Tweari et al., 1979; van Grevenynghe et al., 2003), intracellular killing, ability to 
present antigen, and produce cytokines (van Grevenynghe et al., 2003). This 
study will describe the effects of indirubin derivatives on gene expression, AhR 
signaling pathway, and on select immunologically relevant cellular functions in 
RAW 264.7 macrophages. 
A key turning point in the story of indirubin came in 1999 when Hoessel et 
al. established that indirubin and some of its derivatives (indirubins) can 
competitively bind to the ATP-binding pocket of cyclin-dependent kinases (CDK1 
and CDK2) by means of van der Waals interactions and hydrogen bonding, 
thereby inhibiting their role in cell cycle progression. This finding is the probable 
mechanism through which the anti-leukemic properties of the herbal medicine 
are seen. Although the exact pathway and mechanism of action is not clear, it is 
becoming evident that indirubin(s) act to arrest cells and induce apoptosis by 
means of CDK inhibition, making them a prospective anti-cancer compound. 
The discovery of the cyclin-dependent kinase inhibitory activity of indirubin 
peaked interest in the use and identification of indirubins that have high affinity 
binding to CDKs, therefore becoming potential anti-cancer targets. Indirubin(s) 
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have been found to inhibit proliferation in many human cancer cell lines (Libnow 
et al., 2008), including human tumor cells, through the arrest in G2/M phase by 
blocking the action of CDK2, CDK1 and cyclin B kinase (Marko et al., 2000). 
Recently, Kameswaran et al., (2008) showed that IO increased cell death and 
apoptosis in human laryngeal carcinoma cells by inducing p21, a CDK inhibitor 
protein and further by the inhibition of cyclin D1. Springs et al., (2006) showed 
that Io reduced the p21 gene expression in human U937 cell line. The sudden 
influx of the synthesis of various indirubin derivatives has led to numerous 
reports of selective and potent inhibition of specific cancers. For example, 
meisoindigo has been reported to inhibit microtubule assemblage and DNA 
synthesis in tumor cells (Ji et al 1991) and decrease c-myb gene expression 
thereby inducing leukemic cell differentiation (Liu et al., 1996). Indirubin-N’-
glycosides (Libnow et al., 2008) have showed great promise in arresting several 
cell lines notably the breast cancer cell line MCF-7. Kim et al., (2007) reported 
antitumor activity with 5’-nitro-indirubinozime, 5’-fluoro-indirubinoxime, and 5’ 
trimethylacetamino-indirubinoxime in a Sprague-Dawley rat tumor model.  
Knockaert et al., (2004) showed that IO and various other derivatives, 
including methylated indirubins, rapidly translocate the cytosolic AhR to the 
nucleus. This was an interesting finding because the substituted methyl group 
interferes with the molecules ability to bind to the cyclin-dependent kinase 
catalytic site, and therefore is not an inhibitor of the kinase (Figure 3). This 
suggests that some of the effects on cytotoxicity and cell cycle arrest are 
independent of CDK inhibition and could be AhR-dependent. This is alarming 
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because most compounds that bind to the AhR, for example TCDD and PCB-126 
are highly immunotoxic and carcinogenic (Hankinson, 1995 and Andersson et al 
2002). However, it has been reported that aryl hydrocarbon receptor ligands can 
have both antagonistic and agonistic effects on the AhR signaling pathway 
(Nishiumi et al, 2008). Some ligands that bind to the receptor could induce 
apoptosis and therefore cause growth inhibition in some tumors and cancer cells 
(Bradshaw et al 2002, Damiens et al 2001, and Koliopanos et al 2002). The 
alteration of this pathway in this manner could lead to another mechanism in 
which indirubins could arrest the cell cycle and be beneficial pharmacological 
agents. 
In addition to IO’s role in halting the cell cycle and inducing apoptosis, 
indirubins have been reported to be an anti-inflammatory agent. Hamburger et al 
(2002) reported that leaf extracts from I. tinctoria, an indigo producing plant, 
significantly inhibited cyclooxygenase-2 (COX-2) and iNOS in mast cells. 
Recently a study using extracts as a topical cream on induced contact dermatitis 
in humans showed significantly smaller increase of visual inflammation 
(Heinemann et al., 2004). Kunikata et al (2000) showed a suppression of 
interleukin 6 and interferon gamma inflammatory cytokines in mouse splenocytes 
and human myelomonocytic HBL-28 cells, respectively. They also reported on 
the inhibition of indirubin on induced delayed-type hypersensitivity as 
demonstrated by 2,4,6-trinitro-1-chlorobenzene ear swelling in mice. These 
studies suggest indirubin derivatives are potent anti-inflammatory compounds. 
Sethi et al., (2006) showed that the inflammatory signaling pathway nuclear 
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factor kappa B (NF-kB) is inhibited with the treatment of indirubin through the 
inhibition of IκB kinase and other phosphporylating events.  A similar molecule 
Indol-3-carbinol, a byproduct in plants and cruciferous vegetables, suppresses 
NF-kB and IkB kinase activation, leading to the suppression of several gene 
products including cyclin D1, COX-2, and anti-apoptotic factors (Takada et al., 
2005). 
For the first time the effects indirubins have on gene expression, protein 
expression, and the function of key components of the inflammatory response at 
a cellular level are presented using a relevant RAW 246.7 macrophages in the 
presence and absence of LPS.  
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Figure 2. The dual mechanisms in which indirubins may induce cell cycle arrest 
in dividing cells. (Knockaert et al., 2004)
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Figure 3. Study by Knockaert et al. (2004) on indirubins in comparison with 
TCDD on the interactions in two AhR reporter systems and two kinase assays. 
EC50 and IC 50 values were calculated from dose-response curves in µM amounts. 
* represents compounds inactive at the highest indicated concentration tested.
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MATERIALS AND METHODS 
 
 
Cells and cell culture 
       The murine macrophage cell line RAW 264.7 was obtained from the 
American Type Culture Collection (Manassas, VA) and maintained in Dulbecco’s 
modified Eagle’s medium (DMEM; Cellgro) supplemented with 10% fetal bovine 
serum (Atlas; Fort Collins CO), 10mM HEPES solution, 100mM L-glutamine 
penicillin streptomycin solution, 3 g/L glucose, and 1.5 g/L of sodium bicarbonate, 
each from Sigma (Sigma Aldrich, St. Louis MO, USA). Cells were grown at 37°C 
with 5% CO2 in Corning 75cm2 culture flasks. Unless otherwise noted, each 
experiment had two regimes. A 24 hour regime consisted of cells treated with 
compound alone or simultaneously with compound and ultra pure 
lipopolysaccharide (LPS) (Alexis Biochemical, San Diego CA, USA). A 48 hour 
regime entailed treatment of cells with compound for 48 hours or with compound 
and LPS for the last 24 hour of incubation. 
 
Chemicals 
 
       Specific indirubins and PCB congeners were selected based on the literature 
and predicted structure-activity-relationships (SARs) relevant to AhR binding. 
Compounds were first solubilized in DMSO (Sigma Aldrich) to a stock 
concentration of 10-2 M and diluted to a final working concentration using 
unsupplemented media.  
IR: Indirubin (synthetic) (Alexis Biochemical, San Diego, CA) 
IO: Indirubin-3’-monoxime (A.G. Scientific Inc, San Diego, CA) 
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E804: Indirubin-3’-(2,3 dihydroxypropyl)oximether (Alexis Biochemical, 
San Diego, CA) 
           5Iodo: 5-Iodoindirubin-3’-monoxime (Alexis Biochemical, San Diego, CA) 
PCB-126: 3,3',4,4',5-pentachlorobiphenyl (Ultra Scientific, North Kingston 
RI, USA) 
BIO: 6-Bromoindirubin-3’-oxime (GSK-1 Inhibitor X) (EMD Biosciences 
Inc, San Diego, CA)  
5-Iodo: Indirubin-5-sulphonate. Na (Alexis Biochemical, San Diego, CA) 
PCB-104: 2,4,6,2',6'-pentachlorobiphenyl (Ultra Scientific, North Kingston, 
RI) 
           DMSO: Dimethyl sulphoxide Hybri-Max® (Sigma Aldrich) 
LPS: Lipopolysaccharide from E. coli, Serotype R515 (Re) (ultra pure, 
TLR4grade™) (Alexis Biochemical, San Diego, CA) 
PMA: Phorbol 12-myristate 13-acetate (A.G. Scientific, San Diego, CA) 
 
Experiment: 1. Effective dosage and cell viability 
Cytotoxicity – MTT assay 
Cellular respiration as an indication of viability was measured by MTT (3-
[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide) assay. RAW 264.7 
macrophages and D74 rat glioma cells from the  American Type Culture 
Collection (Manassas, VA) were plated into 96 well Costar plates at 1x105 cells 
per well in 100µl of DMEM media. After 4 hr incubation at 37°C for adherence, 
compounds and DMSO carrier control were added in triplicate at a concentration 
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at serial dilutions of from 10-5 M/well. The cells incubated with compound for 
either 24 or 48 hr. Four hours before termination of experiment each well 
received 20µl of MTT at 5mg/ml in unsupplemented media. After centrifugation, 
the supernatant for each well was discarded and the formazan solubilized with 
100µl of acidified isopropanol. Following a brief period of shaking, the optical 
density for each well was read at wavelength of 550λ on an uQuant microplate 
reader (BioTek Instruments Inc). Data were expressed as percentage of the 
control O.D. values for each experiment. 
 
ApoScreen™ Annexin V Apoptosis Assay 
Since the MTT assay quantify only cellular respiration and viability, and 
not cell death due to apoptosis, apoptosis was quantified by measurement of 
externalized phosphatidylserine residues as detected using an ApoScreen™ 
Annexin V Apoptosis Kit (Southern Biotech, AL, USA). Raw 264.7 murine 
macrophages were seeded at 2.5 x 106 cell/well in 24 well plates for 3 hr for 
adherence, and treated with 1µM indirubin-3’-monoxime, E804, or PCB-126 
alone, or compound and LPS (1µg/ml) for 24 hr.  Other compounds were not 
further tested based on the MTT results. After treatment cells were washed with 
ice-cold PBS and 500µl of Annexin V binding buffer. Binding buffer (100µl) was 
added to all wells, along with 5µl of Annexin V-FITC was added, and the mixture 
incubated for 15 min on ice in the dark. Without washing, 380µL of cold 1X 
binding buffer and 10uL of PI were added to each. After washing the samples, 
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aliquots were processed by flow cytometer using FACScan™ (BD Biosciences, 
San Jose, CA) and 10 000 cells were scored in each event. 
 
Experiement: 2. Gene expression 
rRT PCR Arrays for Stress & Toxicity 
Murine macrophage RAW 264.7 cells were seeded at 5 X 106 cells/ml in 
75 cm2 culture flasks (Corning Inc., NY) and allowed to adhere to flask surfaces 
for 3 hours. Cells were then treated for 24 hr with 1µM of indirubin-3’-monoxime, 
E804, and PCB-126 or compound and LPS. The adhered macrophages were 
scraped from the flask surface using BD FalconTM cell scraper (BD Biosciences, 
Bedford, MA) and harvested by centrifugation. TRI-reagent® was added (1ml) to 
all cell pellets and the mixture was homogenized by gentle pippeting several 
times. The homogenate was incubated at room temperature for 5 min and 0.2 ml 
chloroform added. After incubating the mixture for 15 min, the samples were 
centrifuged at 12,000 g for 15 min at 4°C. The aqueous phase was transferred to 
a new 1.5 ml microcentrifuge tube precipitated with 0.5 ml isopropyl over a 10 
min period, then centrifuged again at 12,000 rpm for 15 min and redissolved in 
DEPC-treated water. After collecting 1mg RNA from each tube, Genomic DNA 
contamination was eliminated by using Genomic DNA elimination mixture 
(SuperArray Bioscience Corporation, Frederick, MD) and cDNA synthesis was 
carried using the RT cocktail (SuperArray Bioscience Corporation, MD). Mouse 
Oxidative Stress RT2 Profiler PCR Array and RT2 Real-Timer SyBR Green/qPCR 
Master Mix were purchased from SuperArray Bioscience Corporation (Frederick, 
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MD). PCR was performed on BioRad iQ5 real-time PCR detection system 
(Applied Biosystems). For data analysis the ∆∆Ct method was used; for each 
gene fold-changes were calculated as difference in gene expression between 
untreated controls and treated cell cultures. A positive value indicates gene up-
regulation and a negative value indicates gene down-regulation. 
 
Experiment: 3 AhR activation 
Translocation of AhR 
 Activation of the aryl hydrocarbon receptor (AhR) was determined by 
fluorescent microscopy (Knockaert, et al., 2004). RAW 264.7 cells were grown in 
minimum essential medium (Cellgro) without phenol red supplemented with 10% 
FBS (Atlas; Fort Collins CO), 10mM HEPES solution, 100mM L-glutamine 
penicillin streptomycin solution, 3 g/L glucose and 1.5 g/L of sodium bicarbonate 
each from Sigma (Sigma Aldrich, St. Louis MO, USA). 100µl of macrophages 
were seeded at 1 x 106 cells/ml in each well of an 8-chambered glass slide 
(Fisher) and were allowed to adhere for 4 hours. Cells were treated for 4 hours 
with 1µM of IO, E804, PCB126, and PCB104. Because the platform design could 
accommodate an additional compound, cells were also treated with 1µM BIO. 
The macrophages were fixed with 3% methanol free paraformaldehyde in HBSS 
for 30 min followed by a brief 5 min treatment with 0.1% sodium borohydride to 
quench auto-fluorescence. Cells were permeablized with 0.1% Triton X (Sigma) 
in HBSS for 30min, then blocked with 3% Fraction V bovine serum albumin for 2 
hours at room temperature in a humidified chamber. Polyclonal anti-AhR primary 
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antibody (Biomol Research Laboratories, Plymoth PA, USA 1:100) was 
incubated overnight at 4°C rocking slowly. FITC conjugated secondary antibody 
was added followed by DAPI labeling. Cells were mounted in 50% glycerol and 
observed on a microscope equipped with a Canon camera on a Zeiss Axiovert 
135 fluorescent microscope (Zeiss Gruppe, Germany). 
 
Experiment: 4 Cellular functions 
Nitric Oxide production 
RAW 264.7 murine macrophages were seeded in 96 well COSTAR plates 
at 1x105 cells per well in Minimum Essential Medium-alpha (MEM) without phenol 
red (Gibco-Invitrogen), supplemented with 4µM L-Arginine. Cells were treated 
with 1µM IO, BIO, E804, PCB-126 or compound and LPS. 100µl aliquots were 
removed from the conditioned medium and incubated in 96 well plates at room 
temperature for 15 min with an equal volume of Griess reagent (equal parts 
Reagent 1; N-(1-naphthyl)ethylenediamine dihydrochloride (NED) and Reagent 
2; Sulfanilamide) (Ding et al, 1988). The absorbance (OD) was measured using 
an uQuant microplate reader (BioTek Instruments Inc) at 550nm. A standard 
curve of known concentration of nitric oxide was made using sodium nitrite. The 
values were averaged and then plotted as a stimulation index against the control 
(Burleson et al 1995).  
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iNOS Western Blot 
Western blot analysis for inducible nitric oxide synthase (iNOS), the 
enzyme responsible for the production of NO,  was determined from RAW 
264.7cell lysates harvested after treatment with IO, BIO, E804, PCB-126 and 
compound with LPS treated cells after 24 hr and 48 hr. The cells were lysed in 
ice cold lysis buffer (50mM Tris, 150 mM NaCl, 1% IGEPAL, 0.1% SDS, pH8) 
supplemented with HALT protease inhibitors (Pierce). The samples were 
centrifuged at 15,000 for 10 min and the supernatant collected. Total protein was 
measured using BCA protein reagent assay (Pierce, Rockford IL). Equal 
concentration (30µl) of protein for each treatment were loaded on lanes of a 4-
20% SDS-PAGE criterion gel (Biorad) at 200 volts then transferred to a 
nitrocellulose membrane (Millipore Corp, Billerica MA). After blocking with BSA 
containing 0.01% gelatin, the membranes were probed with antibody specific for 
iNOS (rabbit anti-iNOS, Signal Transduction Labs, Lexington KY: 1:500) followed 
by goat anti rabbit secondary antibody (1:1000). The blots were then developed 
with NitroBT/BCIP substrate solution. 
 
Interleukin-6 ELISA 
Interleukin-6 (IL-6) production by RAW 264.7 cell supernatant followed by 
treatment was determined by a mouse READY-SET-GO IL-6 ELISA system 
(eBioscience). Briefly, cells were seeded onto a 96 well plate and incubated with 
compound in the presence or absence of LPS for 24hr or 48hr. One hundred µl 
of supernatant were added to a precoated capture antibody Costar maxisorb 
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plate and incubated overnight at 4°C. Detection antibody was added followed by 
treatment of avidin-HRP and a colorimetric substrate solution. A phosphoric acid 
stop solution was added, and the plate read at 450nm on an uQuant microplate 
reader (BioTek Instruments Inc). Concentrations of IL-6 were plotted against the 
standard curve of known concentrations of mouse IL-6 supplied by the 
manufacturer. 
 
Measurement of ROS 
The ability of indirubin(s) to either enhance total reactive oxygen species 
(ROS) production or to modify PMA induced ROS was determined by 
florescence resulting from the oxidation of dichlorodihydrofluorescein diacetate, 
H2DCFDA (Molecular Probes, Eugene, OR) as described by Ding et al. (1988). 
Briefly, cells were seeded onto black 96 well plates at 1 x 105 cells/well using 
MEM without phenol red (Invitrogen). After treatment with compounds or 
compounds with LPS for 24h or 48h, 22µl of 10-4 H2DCFDA was added to all 
wells for 30 min. PMA (10-6M) was added to appropriate wells and incubated for 
an additional 30 min before fluorescent 2’7’-dichlorofluorescin was measured on 
a FLX-800 microplate fluorescence reader (BioTek Instruments, Inc) at excitation 
485nm and emission 528nm (Mattson et al., 1995, revised by Henning et al., 
2002). Data was presented as RFU compared to their controls. 
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Phagocytosis 
Phagocytosis was measured by a modification of previously described 
methods (Bozzaro et al., 1987; Peracino et al., 1998).  RAW264.7 cells were 
added to 96-well round bottom plates at 1 x 105 cells per well in 100µl of 
complete media. Cells then received 100µl of media containing 1µM Io, E804, 
BIO, PCB-126, PCB-104 or carrier control in the presence or absence of LPS. 
After treatments for 24 hr or 48 hr, cells were washed with PBS. Washed 
fluorebrite carboxylate YG, 1 micron,  microspheres (Polyscience, Inc Warrington 
PA, USA) diluted in 50mM Na2HP04, were added to RAW 264.7 cells in the same 
round bottom 96 well plates at a ratio of 100:1 (1 x 107 beads to 1 x 105 cells per 
well), and centrifuged for 5 min for maximal contact. The plates were incubated 
at 37°C for 45min or 90min. Extracellular microspheres (those beads that were 
not phagocytosized) were cleared through extensive washes in a series of 
centrifugations. Phagocytosis was stopped by the addition of 100µl of ice cold 
PBS with 1mM CaCl2 and MgCl2. Plates were centrifuged, the well contents 
removed by aspiration, and replaced with a Ca++/Mg** – free HBSS containing 
0.01% trypsin. Cells were then transferred to an all-black 96 well plate. Trypan 
blue (2mg/ml) dissolved in 20mM citrate and 150mM NaCl, pH 4.5, was added 
for 5 minutes to quench extracellular fluorescence. Plates were then read on a 
FLx-800 fluorescent spectrophotometer at an excitation wavelength of 485nm 
and emission wavelength 528nm. Data were recorded as RFUs relative to the 
control. 
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Lysozyme assay 
Lysozyme activity was measured in RAW 264.7 cell lysates based on 
procedures of Parry et al., (1965) and modified by Burton et al., (2002). Cells 
were seeded onto COSTAR 6 well plates at 2 x 106 per well in DMEM complete 
media and treated  with 1µM IO, E804, PCB-126, PCB-104, or carrier control in 
the presence or absence of LPS for 24 and 48 hr. Cells were then lysed and the 
protein concentration normalized to 1mg/ml. One hundred µl of cell lysate, in 
triplicate, were added onto 96 well plates followed by the addition of 200 µl of 
2mg/ml of heat killed Micrococcus lysodietikus (MP Biomedicals, Solon, Ohio 
USA) in 0.01 sodium phosphate buffer, pH 4.0. The plates were read at 
wavelength 450nm every 5 min for 30minutes, then again at 10 minute intervals 
for an additional 30 minutes. One unit of lysozyme activity was defined as a 
decrease in absorbance of 0.001 min-1. 
 
Bactericidal Assay 
 Intracellular killing of XL-1 Blue E.Coli (Stratagene, La Jolla, CA, USA) by 
RAW 264.7 cells was measured using a novel approach based on Boleza et al., 
(2001) and communication with Stratagene. RAW 264.7 cells were seeded onto 
96 well plates at a concentration of 1 x 105 cells/well under both the 24 hr and 48 
hr  treatment regimes with 1µM Io, BIO, E804, PCB-126 or carrier control  (with 
and without 1µM PMA). Bacteria were grown overnight in LB broth without 
antibiotic, centrifuged and resuspended in sucrose-magnesium buffer (SM buffer) 
to an O.D. of 0.5 at 600nm, which is equivalent to 4 x 108  cells (technical 
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sources from Stratagene). Bacteria were added to the pretreated cells at a ratio 
of 25:1 and incubated for 180 minutes at 37°C. Extracellular bacteria were 
washed away extensively with PBS, and residual bacteria killed by the addition of 
20µl of 10000U Penicillin and 10g/mL steptomyocin solution (Sigma Aldrich) for 
10 min. Cells were then permeablized with 0.1% Tween-20 in PBS for 15 min to 
release the engulfed bacteria. Viable bacteria were grown up in LB broth for 12 
hours at 37°C. The survival of bacterial was measured by a MTT assay. The 
results are presented as the mean of percentage of control treated cells for three 
experiments. 
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RESULTS 
 
Cytotoxicity and effective dosage 
In studies described herein, the anti- or pro-inflammatory effects of select 
indirubin derivatives and reference PCBs were examined in the murine 
macrophage cell line RAW 264.7. Cells were treated with compounds alone or 
with LPS for 24 or 48 hours and endpoints relevant to gene expression, 
transcription factor activation, and functional endpoints were measured.  Since 
the literature on indirubins suggests a pro-apoptotic effect in various cell lines, 
cytotoxicity was first determined in an effort to find a suitable dose for 
subsequent experiments.  As indicated in Figure 4, RAW 264.7 cells are very 
sensitive to indirubins, while the reference cell line D74, a rat glioma line, is 
relatively resistant (Figure 5).   Based on the MTT assay, exposure to levels less 
than 1µM of tested compound were not cytotoxic in terms of affecting cellular 
respiration. Therefore, 1µM was used for all subsequent experiments and 
regimes to determine gene and protein expression, as well as functional cellular 
assays. 
To confirm that 1 uM was not only non-cytotoxic, but non-pro-apoptotic as 
well, annexin-V binding was quantified. The flipping of phosatidylserine to the 
outer cell membrane is indicative of early apoptosis and can be detected through 
the binding and subsequent staining of annexin-V-FITC. As apoptosis continues 
the cell membrane becomes degraded allowing molecules to enter the nuclear 
membrane.  In late apoptosis, cells that have lost membrane integrity can be 
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measured by propidium iodide staining of DNA. The results of annexin-V staining 
coincide with the MTT assay results in that most of the cells after 24h exposure 
to compounds (Figure 6) or compounds with LPS (Figure 7) are viable and not 
labeling annexin-V. 
 
QrRT PCR Arrays for Stress and Toxicity 
 
RT2 Profiler™ PCR microarrays (SuperArray Bioscience Corporation, 
Frederick, MD) for stress and toxicity profile the expression of 84 genes involved 
in oxidative or metabolic stress, proliferation and carcinogenesis, growth arrest 
and senescence, inflammation, and apoptosis. The Array was used to determine 
the effect of indirubin-3’-monoxime, E804, and PCB-126 under the 24 hr regime 
on gene expression in the absence or presence of LPS. The select functional 
gene groupings are shown in Table 1.  The corresponding tables (Table 2-11) 
represent  fold changes in gene expression compared to appropriate control 
(cells alone, or cells treated with only LPS); a negative number indicates a down-
regulation, while a positive number is indicative of an induced gene.  
A notable effect is seen in the expression of inflammatory genes. As 
expected LPS activated macrophages show the increased expression of several 
inflammatory genes (Table 2). Cells treated with indirubin-3’-monoxime alone 
show a decrease in the expression of the NOS2, while E804 and PCB-126 both 
down regulated chemokine ligand 10, TNFb, and Serpine1 compared to cells 
treated without compound.  In cells simultaneously activated with LPS (Table 3) 
indirubin-3’monoxime and E804 shut down the expression of several 
inflammatory genes, including IL-6, while PCB-126 did not. 
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Of interest in the proliferation and carcinogenesis gene groupings (Table 
4) Indirubin-3’-monoxime and E804 decrease the expression of cyclin C and 
cyclin D1, further E804 drastically inhibits  the gene expression of E2F 
transcription factor 1. The expression of proliferation and carcinogenesis genes 
in macrophages activated with LPS consistently showed a decrease in most of 
the genes tested (Table 5). The gene expression of growth arrest and 
senescence, surprisingly, showed an overall decrease in regulation in both 
compound alone and LPS activated cells, notably, p21 and p53, two important 
genes in the regulation of progression of the cell cycle (Table 6 and Table 7).The 
genes involved in apoptotic signaling varied in the expression results, all three 
compounds showed an upregulation of caspase 1 and caspase 8 (Table 7) while 
Bcl2-like 1 and NF-kB inhibitor were downregulated. The suppression of NF-kB 
inhibitor, not surprisingly, due to its important role in many cellular functions, 
Nfkb1 was induced in most treatment scenarios. LPS-activated macrophages 
displayed an overall decrease in the expression of apoptotic genes, E804 and 
PCB-126 showed a dramatic downregulation of Bcl211 (Table 8). However, E804 
did induce Bax.  
E804 was the only compound to show an increase in the expression of the 
cytochrome P450 family of genes (Table 10) while heme oxygenase 1, an 
inducible gene in response to oxidative stress, showed an increase in expression 
in all compounds in all regimes (Table 11). 
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Translocation of AhR  
 To confirm the activation and subsequent translocation of the aryl 
hydrocarbon receptor from the cytoplasm to the nucleus in RAW 246.7 
macrophages, fluorescent microscopy was used.  The derivatives IO (Figure 9), 
BIO (Figure 10), and E804 (Figure 11) each translocated the AhR to the nucleus, 
as well as the well documented AhR ligand PCB-126 (Figure 12).  As expected, 
the AhR in control treated cells (Figure 8) and PCB-104, a non-planar, non AhR-
binding PCB congener, (Figure 13) did not leave the cytoplasm and translocate 
to the nucleus.  
 
Measuring NO, IL-6, and ROS concentrations 
 To determine the effects of indirubins on key players of the inflammatory 
response, several assays were employed. The measurement of nitrate, a stable 
form of nitric oxide was achieved using Greiss reagent.  E804 was the only 
compound that significantly lowered the stimulation index for NO produced by 
LPS-activated macrophages in both time regimes, (Figure 14 and Figure 15).  
iNOS protein expression, as measured by SDS-PAGE and western blotting, 
confirmed the NO production assay. iNOS protein concentrations were reduced 
by exposure to E804 (Figure 16).  E804 also significantly decreased the 
expression of IL-6 (Figure 17 and Figure 18) in LPS activated cells. The 48 hr 
regime showed a decrease in activity for all compounds exposed to activated 
macrophages (Figure 18).  
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The measurement of intracellular ROS was determined by RAW 264.7 
cells ability to cleave H2DCFDA. Most of the indole compounds showed an 
increase in the production of ROS after 24h of exposure (Figure 19). However, 
cells exposed to indirubin-3’-monoxime and BIO under the 48h regime showed a 
decrease in ROS production (Figure 20). 
 
Functional Immunological Endpoints 
 Three functional endpoints were selected due to their importance in 
cellular immunocompetency.  Cellular expression of lysozyme activity, 
phagocytosis of fluorescent latex beads, and intracellular bactericidal assays 
were selected and optimized. To determine lysozyme enzymatic activity the 
ability for RAW 246.7 macrophage cell lysates to clear Micrococcus lysodietikus 
was measured. In LPS-activated cells, E804 decreased the units of enzymatic 
activity after the 24 hr of exposure (Figure 21). Further, after 48 hr (Figure 22) 
cells treated with compound alone and with compound and LPS showed a 
decrease in enzymatic activity. 
 The phagocytic ability of RAW264.7 macrophages to engulf 1 micron 
latex beads after 45 minutes was hindered by all indole compounds tested 
(Figure 23) but not as drastic after 90 minutes (Figure 24). These indirubins 
inhibited intracellular killing of E. Coli in macrophages in the 24 hr regime not 
activated by PMA (Figure 25).  E804 was the only compound that showed 
significant increase in the percentage of surviving bacteria (suppressed 
intracellular killing) for the 48h regime.  
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Figure 4. Cytotoxicity of indirubins, PCB-126, and PCB-104 to RAW 246.7 cells 
after treatment for 24 hours and 48 hours as determined by MTT assay. Data 
represents the percent survival means of three experiments +/- standard error.  
DMSO was included as carrier control. 
  48 
Indirubin-3'-monoxime
0.0 2.5 5.0 7.5 10.0 12.5
0
25
50
75
100
125
Conc (uM)
Pe
rc
en
t S
u
rv
iv
al
BIO
0.0 2.5 5.0 7.5 10.0 12.5
0
20
40
60
80
100
120
Conc (uM)
Pe
rc
en
t S
u
rv
iv
al
E804
0.0 2.5 5.0 7.5 10.0 12.5
0
20
40
60
80
100
120
Conc (uM)
Pe
rc
en
t S
u
rv
iv
al
5-Iodo
0.0 2.5 5.0 7.5 10.0 12.5
0
20
40
60
80
100
120
Conc (uM)
Pe
rc
en
t S
u
rv
iv
al
Indirubin-Sufonic Acid
0.0 2.5 5.0 7.5 10.0 12.5
0
20
40
60
80
100
120
Conc (uM)
Pe
rc
en
t S
u
rv
iv
al
PCB 126
0.0 2.5 5.0 7.5 10.0 12.5
0
20
40
60
80
100
120
Conc (uM)
Pe
rc
en
t S
u
rv
iv
al
PCB 104
0.0 2.5 5.0 7.5 10.0 12.5
0
20
40
60
80
100
120
Conc (uM)
Pe
rc
en
t S
u
rv
iv
al
TbT
0.0 2.5 5.0 7.5 10.0 12.5
0
20
40
60
80
100
120
Conc (uM)
Pe
rc
en
t S
u
rv
iv
al
Figure 5. Cytotoxicity of indirubins, PCB-126, and PCB-104 to D74 glioma cells 
after treatment for 24 hours as determined by MTT assay. Data represents the 
percent survival means of three experiments +/- standard error. Tributyltin 
chloride (TbT) was included as positive cellular toxicity control. 
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Figure 6. Effects of 1µM of compounds on apoptosis in RAW 246.7 macrophages 
as measured by flow cytometry with annexin V (x-axis) and propidium iodide (y-
axis). I- Early apoptosis II-Late apoptosis III-Viable cells, not undergoing 
apoptotic events IV- Early apoptosis. 
Control (Annexin V) 
PCB-126 E804 
Indirubin-3’-monoxime 
I II 
IV III 
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Figure 7. Effects of 1µM of compounds + LPS on apoptosis in RAW 246.7 
macrophages as measured by flow cytometry with annexin V -labeling (x-axis) 
and propidium iodide-labeling (y-axis). I- Early apoptosis  II-Late apoptosis III-
Viable cells, not undergoing apoptotic events IV- Early apoptosis.
LPS 
E804 +LPS 
Indirubin-3’-monoxime + LPS 
PCB-126 + LPS 
I II 
IV III 
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Table 1. Functional Gene Groupings of the Mouse Stress and Toxicity Pathway 
Finder™ RT2 Profiler™ PCR Array. 
  
 
Inflammation: Ccl21b, Ccl3 (MIP-1a), Ccl4 (MIP-1b), Csf2 (GM-CSF), Cxcl10 
(Scyb10), Il1a, Il1b, Il6, Il18, Lta (TNF b), Mif, Nfkb1, Nos2 (iNOS), Serpine1 
(PAI-1).  
Proliferation and Carcinogenesis: Ccnc (cyclin C), Ccnd1 (cyclin D1), Ccng1 
(cyclin G), E2f1, Egr1, Pcna. 
Growth Arrest and Senescence: Cdkn1a (p21Waf1/p21Cip1), Ddit3 
(GADD153/CHOP), Gadd45a, Igfbp6, Mdm2, Trp53 (p53).  
Apoptosis: Anxa5 (annexin v), Bax, Bcl2l1 (bcl-x), Casp1 (Caspase1/ICE), 
Casp8 (caspase8/FLICE), Fasl (Tnfsf6), Nfkbia (ikBa/Mad3), Tnfrsf1a (TNFR1), 
Tnfsf10 (TRAIL), Tradd 
Oxidative or Metabolic Stress: Cryab (a-Crystallin B), cytochrome p450 family, 
Ephx2, Fmo1, Fmo4, Fmo5, Gpx1 (glutathione peroxidase), Gpx2, Gsr 
(glutathione reductase), Gstm1 (glutathione S-transferase mu1), Gstm3, Hmox1, 
Hmox2, Mt2, Polr2k (Mt1a), Por, Sod1, Sod2.  
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Table 2. Altered inflammatory gene expression in RAW 264.7 macrophages 
treated for 24h with 1µM LPS, indirubin-3’-monoxime, E804, or PCB-126 as 
determined by PCR array analysis. Data represents the fold change difference  in 
RFU between compound and control treated cells. 
 
 
GENE LPS IO E804 PCB126 
Chemokine 
ligand 21b 
1.03 -1.06 2.68 1.23 
Chemokine 
ligand 3 
7.17 1.01 4.81 -1.01 
Chemokine 
ligand 4 
190362 25710 633278.7 19791 
Colony-
Stimulating 
factor 2 
27.28 -1.06 2.68 1.23 
Chemokine 
ligand 10 
3.34 1.14 -72.65 -158.9 
Interleukin 18 -1.4 -1.19 -1.16 -1.06 
Interleukin 1 
alpha 
169.9 9.32 2.68 9.44 
Interleukin 1 
beta 
35.45 -1.21 -2.29 1.05 
Interleukin 6 67.89 -1.2 2.38 1.29 
Tumor 
necrosis factor 
beta 
1.53 -1.35 -4.10 -2.2 
Macrophage 
migration 
inhibitory factor 
350089 167864 4862.56 331157 
Nuclear factor 
kappa B (p105) 
16920 9244 6500 7706 
Inducible nitric 
oxide synthase 
10.19 -239.23 2.36 -1.55 
Serpine 1 3.46 1.65 3.31 -2.35 
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Table 3. Altered inflammatory gene expression in RAW 264.7 macrophages 
treated simultaneously with 1µM LPS and indirubin-3’-monoxime, E804, or PCB-
126 for 24h as determined by PCR array analysis. Data represents fold change 
difference in RFU between compound + LPS and LPS treated cells. 
  
 
GENE LPS IO+LPS E804+LPS PCB126+LPS 
Chemokine 
ligand 21b 
1.03 -1.89 -1.47 1.13 
Chemokine 
ligand 3 
7.17 -1.67 -1.7 1.01 
Chemokine 
ligand 4 
190362.2 -1.31 -38.6 -1.21 
Colony-
Stimulating 
factor 2 
27.29 -2.83 -1.64 1.28 
Chemokine 
ligand 10 
3.34 -2.17 -928.16 1.16 
Interleukin 18 -1.4 -2.06 -1669.83 1.17 
Interleukin 1 
alpha 
169.9 -1.28 -14.75 -146.55 
Interleukin 1 
beta 
35.45 -1.43 -1.89 1.5 
Interleukin 6 67.89 -140.87 -1.94 1.46 
Tumor 
necrosis factor 
beta 
1.53 -2.94 1.27 -1.47 
Macrophage 
migration 
inhibitory factor 
350089.6 -3.47 -1.39 1.06 
Nuclear factor 
kappa B (p105) 
16920.76 -1.63 -1.48 -2 
Inducible nitric 
oxide synthase 
10.19 -1.27 -1.35 -1.16 
Serpine 1 3.46 -1.51 -1.01 -1.34 
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Table 4. Altered proliferation and carcinogenesis gene expression in RAW 264.7 
macrophages treated for 24h with 1µM LPS, indirubin-3’-monoxime, E804, or 
PCB-126 as determined by PCR array analysis. Data represents the fold change 
difference in RFU between compound and control treated cells. 
 
 
 
GENE LPS IO E804 PCB126 
Cyclin C -1.21 -1509 -335.31 1.01 
Cyclin D1 -1.51 -2366 -3.564.05 -1.06 
Cyclin G1 -1.07 -15.34 7.2 1.4 
E2f transcription 
factor 1 
-1.18 1.09 -968.65 -1.62 
Early growth 
response 1 
8989 1208 2.68 3734 
Proliferating cell 
nuclear antigen 
15.98 4.91 -5 -1967 
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Table 5. Altered proliferation and carcinogenesis gene expression in RAW 264.7 
macrophages treated simultaneously with1µM LPS and indirubin-3’-monoxime, 
E804, or PCB-126 for 24h as determined by PCR array analysis. Data represents 
the fold change difference in RFU between compound + LPS and LPS treated 
cells. 
  
 
 
 
 
GENE LPS IO+LPS E804+LPS PCB126+LPS 
Cyclin C -1.21 -1385.62 -1072.65 -649.7 
Cyclin D1 -1.51 -7792.47 1.02 -1.13 
Cyclin G1 -1.07 -26.45 -11.9 -4197.59 
E2f 
transcription 
factor 1 
-1.18 -1.55 -3201.7 -1.08 
Early growth 
response 1 
8989 -1.83 -1.81 1.26 
Proliferating cell 
nuclear antigen 
15.98 -8.46 -1.27 -1.06 
 
  56 
 
Table 6. Altered growth arrest and senescence gene expression in RAW 264.7 
macrophages treated for 24h with 1µM LPS, indirubin-3’-monoxime, E804, or 
PCB-126 as determined by PCR array analysis. Data represents the fold change 
difference in RFU between compound and control treated cells. 
 
  
 
 
GENE LPS IO E804 PCB126 
Cyclin-
dependent 
kinase inhibitor 
1a (p21) 
-1.06 -4.26 -3.92 1.12 
DNA-damage 
inducible 
transcript 3 
(Ddit3) 
2.09 -56.39 -7.77 -1.2 
Growth arrest 
and DNA-
damage-
inducible 45 
alpha 
2.75 -22.54 -5.34 -1.2 
Insulin-like 
growth factor 
binding protein 6 
1.01 -1.68 2.68 1.33 
Transformed 
mouse 3T3 cell 
double minute 2 
25458 10705 2.68 14380 
p53 1.15 -5.93 -6387 -1.05 
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Table 7. Altered growth arrest and senescence gene expression in RAW 264.7 
macrophages treated simultaneously with1µM LPS and indirubin-3’-monoxime, 
E804, or PCB-126 for 24h as determined by PCR array analysis. Data represents 
the fold change difference in RFU between compound + LPS and LPS treated 
cells. 
  
 
 
 
GENE LPS IO+LPS E804+LPS PCB126+LPS 
Cyclin-
dependent 
kinase inhibitor 
1a (p21) 
-1.06 -3.34 1.13 1.09 
DNA-damage 
inducible 
transcript 3 
(Ddit3) 
2.09 -20.46 -2.3 1.19 
Growth arrest 
and DNA-
damage-
inducible 45 
alpha 
2.75 -9.07 -1.64 1.44 
Insulin-like 
growth factor 
binding protein 6 
1.01 -1.89 -1.46 1.13 
Transformed 
mouse 3T3 cell 
double minute 2 
25458 -1.67 -1.95 -17.66 
p53 1.15 -8.69 -1.35 -1.12 
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Table 8. Altered apoptosis gene expression in RAW 264.7 macrophages treated 
for 24h with1µM LPS, indirubin-3’-monoxime, E804, or PCB-126 as determined 
by PCR array analysis. Data represents the fold change difference in RFU 
between compound and control treated cells. 
 
 
 
 
GENE LPS IO E804 PCB126 
Annexin A5 91288 94751 1733843 98147 
Bcl2-associated 
X protein 
-1.05 -1.22 3.95 -11926 
Bcl2-like 1 2.55 -1364 -302.91 -1.55 
Caspase 1 6462 2076 446703 1.33 
Caspase 8 418.16 399 265.75 420 
Fas ligand 1.01 -1.68 2.68 1.33 
Nuclear factor 
kappa B 
inhibitor 
2.88 -6.07 -13.53 1.3 
Tumor necrosis 
factor receptor 
1a 
1.2 -1.32 -756 -2.3 
Tumor necrosis 
factor receptor 
10 
2.13 2.61 2.68 4.6 
TNFRSF1A-
associated 
death domain 
-1.0 -1.1 5.74 1.38 
 
  59 
 
Table 9. Altered apoptosis gene expression in RAW 264.7 macrophages treated 
simultaneously with 1µM LPS and indirubin-3’-monoxime, E804, or PCB-126 for 
24h as determined by PCR array analysis. Data represents the fold change 
difference in RFU between compound and LPS treated cells. 
  
 
 
GENE LPS IO+LPS E804+LPS PCB126+LPS 
Annexin A5 91288 -1.12 -1.09 1.19 
Bcl2-associated 
X protein 
-1.05 1.04 -21897.7 -13263.5 
Bcl2-like 1 2.55 -3879.33 -1.35 -1818.97 
Caspase 1 6462 -3.25 -1.39 1.26 
Caspase 8 418.16 -1.68 -1.37 1.06 
Fas ligand 1.01 -1.89 -1.46 1.13 
Nuclear factor 
kappa B 
inhibitor 
2.88 -6.27 1.01 1.15 
Tumor necrosis 
factor receptor 
1a 
1.2 -1.72 1.1 -2129.69 
Tumor necrosis 
factor receptor 
10 
2.13 -1.88 -3.08 1.02 
TNFRSF1A-
associated 
death domain 
-1.0 -1.64 -1.5 1.13 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  60 
 
Table 10. Altered oxidative and metabolic gene expression in RAW 264.7 
macrophages treated for 24h with 1µM LPS, indirubin-3’-monoxime, E804, or 
PCB-126 as determined by PCR array analysis. Data represents the fold change 
difference in RFU between compound and control treated cells. 
 
 
GENE LPS IO E804 PCB-126 
Crystallin B 
 
1.01 -1.68 
 
2.68 
 
1.33 
 
Cytochrome 
P450 family 
1.01 -1.68 
 
2.68 1.33 
 
Epoxide 
hydrolase 2 
1.01 -1.68 
 
2.68 1.33 
 
Flavin containing 
monoxygenase 1 
1.01 -1.68 
 
2.68 1.33 
 
Flavin containing 
monoxygenase 4 
5.23 -1.68 
 
2.68 1.33 
 
Flavin containing 
monoxygenase 5 
-1.75 -243.35 
 
-54.06 
 
1.38 
 
Glutathione 
peroxidase 1 
-1.37 -2.41 
 
-32.58 
 
1.09 
Glutathione 
peroxidase 2 
-2.21 1.3 -3.42 
 
-1.01 
 
Glutathione 
reductase 
-1.05 -23.22 
 
2.25 -1.74 
 
Glutathione S-
transferase mu1 
-1.15 -2281 
 
-507 
 
-1.51 
 
Glutathione S-
transferase mu3 
1.01 -1.68 
 
2.68 1.33 
 
Heme 
oxygenase 1 
1.01 2729 
 
1582.53 
 
1.33 
 
Heme 
oxygenase 2 
1.07 -2.28 
 
1.10 1.33 
Metallothionein 2 
 
1.52 -1.27 -4.96 -1.02 
 
Polymerase II 
polypeptide K 
-1.21 -237 
 
8.9 
 
1.62 
 
P450 
oxidoreductase 
1.29 -1.68 
 
1.81 
 
-1578 
 
Superoxide 
dismutase 1 
66465 312 
 
323782 
 
99398 
 
Superoxide 
dismutase 2 
2.05 -7.26 
 
-457.67 
 
-922 
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Table 11. Altered oxidative and metabolic stress gene expression in RAW 264.7 
macrophages treated simultaneously with1µM LPS and indirubin-3’-monoxime, 
E804, or PCB-126 for 24h as determined by PCR array analysis. Data represents 
the fold change difference in RFU between compound + LPS and LPS treated 
cells. 
 
 
GENE LPS IO + LPS E804 + LPS PCB-126 + 
LPS 
Crystallin B 
 
1.01 -1.89 
 
-1.46 
 
1.13 
 
Cytochrome 
P450 family 
1.01 -1.89 
 
-1.46 
 
1.13 
 
Epoxide 
hydrolase 2 
1.01 -1.89 
 
-1.46 
 
1.13 
 
Flavin containing 
monoxygenase 1 
1.01 -1.89 
 
-1.46 
 
1.13 
 
Flavin containing 
monoxygenase 4 
5.23 -9.79 
 
-7.58 
 
-1.19 
 
Flavin containing 
monoxygenase 5 
-1.75 -155.48 
 
-1.21 
 
1.86 
 
Glutathione 
peroxidase 1 
-1.37 -3.67 
 
-1.48 
 
-1.47 
 
Glutathione 
peroxidase 2 
-2.21 1.49 
 
-2.52 
 
1.41 
 
Glutathione 
reductase 
-1.05 -3.51 
 
1.84 
 
1.84 
 
Glutathione S-
transferase mu1 
-1.15 -2.17 
 
-1.36 
 
-1.18 
 
Glutathione S-
transferase mu3 
1.01 -1.89 
 
-1.46 
 
1.13 
 
Heme 
oxygenase 1 
1.01 6529.36 
 
6448.8 
 
6798.29 
 
Heme 
oxygenase 2 
1.07 -2.51 
 
-1.15 
 
1.07 
 
Metallothionein 2 
 
1.52 -1.6 
 
-1.55 
 
225352 
 
Polymerase II 
polypeptide K 
-1.21 -326.06 
 
-1.06 
 
1.2 
 
P450 
oxidoreductase 
1.29 -1.32 
 
1.1 
 
1.02 
 
Superoxide 
dismutase 1 
66465 -147.65 
 
-1.49 
 
-1.03 
 
Superoxide 
dismutase 2 
2.05 -6.77 
 
-1.69 
 
-2189.75 
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Figure 8. Nuclear translocation of AhR in RAW246.7 cells treated with media 
control for 4 hours. DAPI was used to stain nuclear DNA. (A- AhR FITC staining, 
B- DNA DAPI staining, C- Merged AhR+DAPI images, D- white light). Sale bar, 
10µm. 
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Figure 9. Nuclear translocation of AhR in RAW246.7 cells treated with 1µM 
indirubin-3’-monoxime for 4 hours. DAPI was used to stain nuclear DNA. (A- AhR 
FITC staining, B- DNA DAPI staining, C- Merged AhR+DAPI images, D- white 
light). 
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Figure 10. Nuclear translocation of AhR in RAW246.7 cells treated with 1µM BIO 
for 4 hours. DAPI was used to stain nuclear DNA. (A- AhR FITC staining, B- DNA 
DAPI staining, C- Merged AhR+DAPI images, D- white light). 
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Figure 11. Nuclear translocation of AhR in RAW246.7 cells treated with 1µM 
E804 for 4 hours. DAPI was used to stain nuclear DNA. (A- AhR FITC staining, 
B- DNA DAPI staining, C- Merged AhR+DAPI images, D- white light).  
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Figure 12. Nuclear translocation of AhR in RAW246.7 cells treated with 1µM 
PCB126, a positive AhR ligand control, for 4 hours. DAPI was used to stain 
nuclear DNA. (A- AhR FITC staining, B- DNA DAPI staining, C- Merged 
AhR+DAPI images, D- white light). 
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Figure 13. Nuclear translocation of AhR in RAW246.7 cells treated with 1µM 
PCB104, a non planar AhR ligand negative control, for 4 hours. DAPI was used 
to stain nuclear DNA. (A- AhR FITC staining, B- DNA DAPI staining, C- Merged 
AhR+DAPI images, D- white light). 
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Figure 14. Nitric oxide stimulation in RAW 264.7 cells treated for 24h with 
indirubins or PCB-126. White bars indicate the effect of compound alone on the 
macrophage model, while black bars indicate simultaneous treatment of 
compound and LPS. ** represents p ≤0.01. 
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Figure 15. Nitric oxide stimulation in RAW 264.7 cells treated for 48h with 
indirubins or PCB-126. White bars indicate the effect of compound alone on the 
macrophage model, while black bars indicate simultaneous treatment of 
compound and LPS. * represents p ≤0.05. 
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Figure 16. iNOS protein expression in RAW 264.7 cells following exposure to 24h 
regime treatment (a) and 48h regime treatment (c). Cells were treated, lysed, and 
subjected to SDS-PAGE and probed for iNOS protein (a,c) or actin protein (b,d). 
Lane 1, control; lane 2, LPS control; lane 3, Io; lane 4, Io+ LPS; lane 5, BIO; lane 
6, BIO + LPS; lane7, E804; lane 8, E804 +LPS, lane 9, PCB126; lane 10 
PCB126 + LPS. 
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Figure 17. The effects of indirubins and PCB-126 on the production of the 
inflammatory cytokine IL-6 on RAW 264.7 macrophages (white bars) and LPS-
stimulated macrophages (black bars) treated with the 24h regime. Data 
represents the mean +/- the standard error. ** represents p ≤0.01, * represents p 
≤0.05 compared to appropriate control. 
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Figure 18. The effects of indirubins and PCB-126 on the production of the 
inflammatory cytokine IL-6 on RAW 264.7 macrophages (White bars) and LPS-
stimulated macrophages (Black bars) treated with the 24h regime. Data 
represents the mean +/- the standard error. ** represents p ≤0.01, * represents p 
≤0.05 compared to appropriate control. 
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Figure 19. The effects of indirubins and PCB-126 on reactive oxygen 
intermediate production in RAW 246.7 macrophages (black bars) and PMA-
stimulated macrophages (white bars) treated with the 24h regime with three 
different concentrations of compound. Data represents the mean +/- the standard 
error of the percent control cells treated without compound.  ** represents p 
≤0.01, * represents p ≤0.05 compared to appropriate control. 
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Figure 20. The effects of indirubins and PCB-126 on reactive oxygen 
intermediate production in RAW 246.7 macrophages (white bars) and PMA-
stimulated macrophages (black bars) treated with the 48h regime using three 
different concentrations of compound. Data represents the mean +/- the standard 
error of the percent control cells treated without compound.  * represents p ≤0.05 
compared to appropriate control. 
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Figure 21. The effects of 1µM indirubins and PCB-126 on phagocytosis 
incubated for 45min or 90min with FITC-labeled latex beads; treated under the 
24h regime. Data represents the percent control mean from three experiments 
+/- the standard error. ** represents p ≤0.01, * represents p ≤0.05 as compared 
to appropriate control. 
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Figure 22. The effects of 1µM indirubins and PCB-126 on phagocytosis 
incubated for 45min or 90min with FITC-labeled latex beads; treated under the 
48h regime. Data represents the percent control mean from three experiments 
+/- the standard error. * represents p ≤0.05 as compared to appropriate control. 
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Figure 23.  The effects of 1µM indirubin-3’monoxime and E804 on lysozyme 
activity in RAW 246.7 macrophages (white bars) and LPS-activated 
macrophages (black bars) treated with the 24h regime. Data represents the 
means +/- standard error. ** represents p ≤ 0.01. 
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Figure 24. The effects of 1µM indirubin-3’monoxime and E804 on lysozyme 
activity in RAW 246.7 macrophages (white bars) and LPS-activated 
macrophages (black bars) treated with the 48h regime. Data represents the 
means +/- standard error. ** represents p ≤ 0.01, * represents p ≤ 0.05. 
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Figure 25. The effects of 1µM indirubins and PCB-126 on intracellular bacterial 
killing in RAW 264.7 macrophages under both 24h and 48h regimes. Data 
represents the mean of three experiments +/- standard error. * represents p 
≤0.05 as compared to appropriate control. 
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DISCUSSION 
 
 
 Based on a large literature base that supports the utility of the murine 
macrophage cell line, RAW 264.7, in the field of immunopharmcology, this cell 
line was used to examine the effects of IO and E804, as well as BIO in some 
cases, on macrophage inflammation-like functions.  Because many of the 
reported affects of these compounds on the biology of cells have been linked to 
the AhR, this study also used the coplanar halogenated hydrocarbon PCB-126, 
which is a potent AhR agonist. Moreover, when appropriate, the non-coplanar 
congener PCB-104 was used as a negative control for PCB-126.  This work 
bridges the existing gap between the effects of treatments on alteration of gene 
expression and cellular function in RAW 264.7 cells by indirubins. 
As with previous work in this lab (Springs and Rice, 2006), concentrations 
of 1 µM for each compound were not cytotoxic, even for up to 48 hr of treatment.  
This turns out to be fortuitous because these compounds can be compared on a 
molecule-to-molecule level, based on Avagadro’s number. One of the most 
interesting early observations was that RAW 264.7 cells are far more sensitive to 
indirubins than D74 glioma cells, suggesting that macrophages are more 
sensitive than undifferentiated and anaplastic cell lines. Earlier work in this lab 
used U937 cells, which are human histiocytes that can be differentiated into 
macrophage-like cells via exposure to PMA. As with the RAW 264.7 cell line, 
U937 cells seem to be more sensitive to indirubin toxicity as they become more 
differentiated. Flow cytometry results also indicated that after 24h exposure to IO, 
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E804, PCB-126 and LPS most of the cells are not undergoing apoptosis and are 
viable. 
It has been well established that planar hydrocarbons are ligands for the 
aryl hydrocarbon receptor (AhR). The potency of AhR signaling is dependent on 
the affinity of the compound for the receptor. As a case in point, TCDD has the 
highest known affinity, PCB-126 and other coplanar halogenated hydrocarbons 
have a potency (affinity for the AhR) ranging from 1/10th to 1/1000th of TCDD 
(Kafafi, et al., 1993). Most of the known and well characterized high affinity 
ligands for the AhR are anthropogenic, but the affinity of natural (endogenous?) 
compounds to the AhR is still uncertain. However, recently a reporter yeast 
system showed that indirubin, a planar hydrocarbon, found naturally in plants, 
mollusks, bacteria, and human urine binds to the AhR with an affinity higher than 
TCDD (Adachi, et al., 2001). However, in whole-cell systems the potency of 
indirubin is lower than what is seen in reporter systems.  
As previously reported, indirubin-3’-monoxime and other derivatives are 
able to activate  the aryl hydrocarbon receptor, causing it to translocate to the 
nucleus (Adachi et al., 2001; Spink et al., 2003; Knockaert et al., 2004; Springs 
and Rice 2006) and promote the transcription of genes associated with the 
xenobiotic response element. To date, all ligands that bind to the AhR induce the 
drug metabolizing CYP1A-family of enzymes. Although gene expression did not 
show an increase for the cytochrome P450 family of enzymes in cells exposed to 
IO or PCB-126, there was a 2.68 fold increase when treated with E804 alone for 
24 hours.  This is not surprising because Springs et al. (2006) reported maximum 
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expression of CYP1A1 in undifferentiated U937 cells compared with low levels of 
expression in fully differentiated cells also treated with LPS. Though much of the 
historical attention has focused on indirubin, and it’s synthetic derivative IO, it is 
clear from this study that E804 is extremely potent in terms of it’s affinity for the 
AhR.  
The induction of CYP genes by high affinity ligands to the AhR creates 
oxidative stress within the cell due to leakage of oxygen radicals as the 
monooxygenases consume oxygen (Whitlock 1993). In general, one of the most 
severe toxic endpoints of strong AhR ligands is uncontrolled oxidative stress 
(Radjendirane et al., 1999). Recently it was reported that AhR ligands interact 
with the Nrf2 gene battery which encodes enzymes responsible for oxidative 
stress (Kohle et al., 2007). Studies suggest that Nrf2 is a direct target gene for 
the AhR (down-stream of the response element), and thus is transcribed along 
with other members of the “gene cassette” that includes CYP1a1, Cyp1a2, and 
Cyp1b1.  Therefore, it is not surprising to see an increase in the expression of 
heme oxygenase 1 (Hmox1) and superoxide dismutase 1 (Sod1) and other 
stress related genes after exposure to IO, E804, and in PCB-126.  
Both IO and E804 increased ROS production in RAW 264.7 cells after 24 
hours, which is in line with Green et al. (2008) who, observed that the dioxin-like 
PCBs induce Cyp1a1 and Cyp1b1 genes and intracellular production of ROS.  
However, ROS production in IO and E804 treated cells was reduced after 48 hr, 
indicating that several radical scavenging mechanisms were involved. Length of 
time may be a factor, as activation of AhR also triggers the expression of aryl 
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hydrocarbon receptor repressor, AhRR. The repressor acts as a negative 
feedback loop blocking the transcription of XRE genes by competitively inhibiting 
the interaction with ARNT (Evans et al., 2008).  Alternatively, and more likely, the 
radical scavenging system was able to abate oxidative stress.  As part of the 
experimental design, cells were also treated with PMA for 30 minutes just before 
measuring ROS production.  In primary macrophages, and especially 
neutrophils, PMA acts as a diacyl-glycerol (DAG) mimic and activates protein 
kinase C (PKC).  PKC then activates the membrane-associated NADPH-oxidase 
system, which in turn converts molecular O2 to ROS such as superoxide anion.  
Superoxide anion is further reduced to hydrogen peroxide by superoxide 
dismutase (SOD).  Since RAW 264.7 cells are not primary macrophages, they 
may not possess the ability to respond to PMA in the same fashion, therefore 
explaining why PMA-treatment did not result in large amounts of ROS 
generation. 
Activation and translocation of the AhR to the nucleus was seen within 
four hours of exposure to IO, BIO, E804, and PCB-126.  PCB-104 was used as a 
negative halogenated hydrocarbon control; the non-planar (globular) 
configuration of the molecule inhibits its binding with the receptor.   Using 
antibody-labeling for the AhR has become a gold standard for showing activation 
and translocation following treatment (Knockaert, et al., 2004); however, this 
technique alone does not show transcription factor binding to its particular 
response element.  Future studies with E804 and other experimental AhR ligands 
should (and will) include ChiP assays and possibly electrophoretic mobility shift 
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assays (EMSAs).  Still, as a screening mechanism, cytosolic vs nuclear staining 
of the AhR is a quick and efficient method for identifying AhR ligands. 
AhR signaling is not only involved in toxicity and oxidative stress, it plays a 
role in several different pathways including cell cycle regulation, development, 
and immunity (Marlowe et al., 2005). TCDD has been shown to decrease cyclin 
D1 levels and CDK-dependent kinase activities (Wang et al., 1998), as have 
other AhR ligands.   The end effect of decreased cyclin D1 and CDK-dependent 
kinases is cell cycle arrest (Reiners et al., 1999).  
Hoessel et al. (1999) reported that indirubin is a cyclin-dependent kinase 
inhibitor, leading to the arrest of the cell cycle by competitively binding to the ATP 
catalytic site of the kinase. The interaction and concentration levels of cyclins and 
cyclin-dependent kinases regulate the cell cycle progression in all eukaryotic cell 
studies to date.  In this study, Cyclin C, Cyclin D1, and Cyclin G were all inhibited 
by the treatment of IO and E804, but treatment with PCB-126 alone did not. This 
finding suggests that the halting of the cell cycle, at least in part, is independent 
of AhR signaling and could be due to the regulation of cyclins and inhibition of 
kinases.  
The E2F family regulates the progression of the cell cycle, and there are 
two subgroups divided into activating and repressing transcription factors.  E2F1 
is a major component in progressing the cell during the G1/S phase. The 
hyperphosphorylated retinoblastoma (Rb) factor remains bound to E2F until 
cyclin D/CDK4 releases its inhibition. This allows E2F to function as a positive 
transcription factor increasing several factors needed to progress into the S 
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phase. Studies have indicated that the activated AhR can bind to Rb and 
suppress E2F activity (Puga et al., 2000). A decrease in this key factor would halt 
the cell cycle in the G1/S phase.  E804 dramatically decreased the expression of 
E2F1 gene, indicating that E804 might be a promising anti-cancer drug with an 
array of mechanisms for halting the cell cycle. 
The herbal remedy in which indirubin is the active ingredient, not only 
showed promising results in terms of cancer and detoxification but also chronic 
inflammation. It has been previously reported that indirubin inhibits the gene 
expression of inducible nitric oxide and cyclooxygenase in mast cells (Hamburger 
et al., 2002).  Studies have also shown that indirubin suppresses IL-6 and IFN-γ 
production in mouse splenocytes and human myelomonoctic cell lines, as well as 
an inhibition on induced-delayed-type hypersensitivity in mice (Kunikata et al., 
2000).  The study herein showed that expression of several inflammatory genes 
was decreased in cells treated with IO and E804. Notably, NOS2 and IL-6 genes 
were down-regulated. This corresponds well with the functional protein assays as 
seen in nitric oxide (NO) and IL-6. NO is a product of iNOS that has an important 
role in killing of intracellular bacteria and other pathogens. IL-6 is a key 
inflammatory cytokine that is released from macrophages in response to antigen 
activating the Toll-like receptor singling pathway production of several 
inflammatory mediators. The gene expression for IL-6 in E804 treated cells is 
induced after 24h of treatment, however the functional assay showed an 
inhibition of IL-6 activity. This finding shows the importance of researching not 
only gene expression but protein function as well. E804 inhibits the cytokine 
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cytoplasmic Stat signaling cascade of IL-6 by inhibiting Src kinase activity (Nam 
et al., 2005).  Therefore, although the gene expression of the cytokine may not 
be suppressed, the down-stream signaling activity of the cytokine is modified. A 
novel finding from this study indicates that E804 is a more potent inhibitor of 
inflammatory functions and gene expression than its more famous IO 
counterpart.  
The NF-κB pathway is known as the central mediator of the innate 
immune system. Most carcinogens and inflammatory agents activate NF-κB 
through the degradation of its inhibitor IκB by IκB-kinase (IKK). It is then 
translocated to the nucleus where it is involved in the expression of several gene 
products including anti-apoptotic genes such as SURVIVIN, TRAF, BCL2, and 
BCLxL, several inflammatory cytokines, and cell cycle genes including cyclin D1. 
Sethi et al. (2006) reported that indirubin inhibits IKK degradation as well as the 
phosporylation of p65, which is required for the translocation of NF-κB.  The 
study herein showed that IO and E804 had a dramatic effect on the expression of 
several genes that are regulated by NF- κB including the antiapoptotic gene 
BCLx, inflammatory cytokines IL-6, IL-1, and IL-18, as well as cell cycle 
regulators Cyclin C and Cyclin D1. This suggests that the inhibition of NF-κB 
signaling cascade could be the major mechanism by which these compounds 
exert anti-inflammatory function.  
The ability for RAW 264.7 macrophages to phagocytosize fluorescent 
latex beads over a 45 min period was inhibited by all the indirubins. However, 
after 90 min only BIO showed inhibition.  It is evident from several previous 
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reports that AhR ligands inhibit phagocytosis in macrophages.  van Grevenynghe 
et al. (2003) reported that PAHs inhibit the macrophage’s ability to differentiate 
into an active phagocytic macrophage in the presence of colony stimulating 
factors. Others have shown that IO (Springs and Rice, 2006) and 3’-
methylcholantherene (Tewari et al., 1979) (a potent AhR ligand) suppress 
phagocytosis in murine macrophages. The mechanisms in which indirubins and 
other AhR ligands affect phagocytosis needs to be further examined.   
Although indirubins may exert their effects through several diverse 
pathways, it is becoming easier to develop indirubin derivatives with specific 
activity towards one particular receptor or target. For example, brominated 
indirubins bind with high affinity to GSK-3 (Meijer et al., 2003; Polychronopoulos 
et al., 2004), while other derivatives bind to CDKs with higher affinity (Hoessel et 
al., 1999; Moon et al., 2006). Recent studies show that methylated indirubins 
have reduced binding to kinases, however they are potent ligands of the AhR 
(Knockaert, et al., 2004). From a pharmacological standpoint, indirubins have 
great potential for therapeutic applications by exploiting their selectivity towards a 
particular kinase, receptor, or target, without the activation of other toxic 
pathways.   To date, however, none of the derivatives of indirubin lack AhR 
binding activity, suggesting that the AhR may be a critical target, and have a 
critical role in future anti-cancer and anti-inflammatory drug design approaches. 
This is the first study that simultaneously examined the effects of multiple 
indirubins on gene expression and corresponding cellular function in 
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macrophages.  Of the indirubin derivatives examined, E804 was the most potent 
in terms of biological effects. 
In conclusion: 
 IO, E804, and BIO bind to, and activate the AhR leading to it’s 
translocation to the nucleus. 
 IO and E804, but not PCB-126 suppressed the expression of genes 
associated with cell cycling.  E804 exposure drastically suppressed 
expression of the E2f1 gene, indicating at least one mechanism of effect 
that is independent of the AhR.  
 E804 is a more potent inhibitor of inflammatory genes, proteins, and 
cellular functions than was has been reported for indirubin or indirubin-3’-
monoxime. 
 Indirubins affect normal cellular functions in RAW 264.7 cells in terms of 
phagocytosis and intracellular killing. 
 This investigation revealed that E804 has more significant effects and 
clinical promise than its more famous counterpart indirubin-3’-monoxime. 
 From a pharmacological standpoint, indirubins show great promise as 
anti-cancer, anti-inflammatory, and detoxification compounds.  
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                                             APPENDIX 
Scatter plots of altered gene expression in RAW 264.7 macrophages. Data 
represents RFU fold changes compared to control. 
 
Figure 25. Scatter plot of the effects of LPS on RAW 264.7 macrophage 
inflammatory related gene expression. Data represents the fold change in RFU 
between LPS and control treated cells. 
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Figure 26. Scatter plot of the effects of 1µM Io on RAW 264.7 macrophage 
inflammatory related gene expression. Data represents the fold change in RFU 
between Io and control treated cells. 
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Figure 27. Scatter plot of the effects of 1µM E804 on RAW 264.7 macrophage 
inflammatory related gene expression. Data represents the fold change in RFU 
between E804 and control treated cells. 
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Figure 28. Scatter plot of the effects of 1µM PCB-126 on RAW 264.7 
macrophage inflammatory related gene expression. Data represents the RFU 
fold change between PCB-126 and control treated cells. 
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Figure 29. Scatter plot of the effects of 1µM Io + LPS on RAW 264.7 macrophage 
inflammatory related gene expression. Data represents the fold change in RFU 
between Io + LPS and LPS treated cells. 
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Figure 30. Scatter plot of the effects of 1µM E804 + LPS on RAW 264.7 
macrophage inflammatory related gene expression. Data represents the fold 
change in RFU between E804 + LPS and LPS treated cells. 
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Figure 31. Scatter plot of the effects of 1µM PCB-126 + LPS on RAW 264.7 
macrophage inflammatory related gene expression. Data represents the fold 
change in RFU between PCB-126 + LPS and LPS treated cells. 
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Figure 32. Scatter plot of the effects of LPS on RAW 264.7 macrophage 
proliferation and carcinogenesis related gene expression. Data represents the 
fold change in RFU between LPS and control treated cells. 
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Figure 33. Scatter plot of the effects of 1µM Io on RAW 264.7 macrophage 
proliferation and carcinogenesis related gene expression. Data represents the 
fold change in RFU between Io and control treated cells. 
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Figure 34. Scatter plot of the effects of 1µM E804 on RAW 264.7 macrophage 
proliferation and carcinogenesis related gene expression. Data represents the 
fold change in RFU between E804 and control treated cells. 
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Figure 35. Scatter plot of the effects of 1µM PCB-126 on RAW 264.7 
macrophage proliferation and carcinogenesis related gene expression. Data 
represents the fold change in RFU between PCB-126 and control treated cells. 
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Figure 37. Scatter plot of the effects of 1µM Io + LPS on RAW 264.7 macrophage 
proliferation and carcinogenesis related gene expression. Data represents the 
fold change in RFU between Io + LPS and LPS treated cells. 
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Figure 38. Scatter plot of the effects of 1µM E804 + LPS on RAW 264.7 
macrophage proliferation and carcinogenesis related gene expression. Data 
represents the fold change in RFU between E804 + LPS and LPS treated cells. 
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Figure 39. Scatter plot of the effects of 1µM PCB-126 + LPS on RAW 264.7 
macrophage proliferation and carcinogenesis related gene expression. Data 
represents the fold change in RFU between PCB-126 + LPS and LPS treated 
cells. 
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Figure 40. Scatter plot of the effects of LPS on RAW 264.7 macrophage growth 
arrest and senescence related gene expression. Data represents the fold change 
in RFU between LPS and control treated cells. 
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Figure 41. Scatter plot of the effects of 1µM Io on RAW 264.7 macrophage 
growth arrest and senescence related gene expression. Data represents the fold 
change in RFU between LPS and control treated cells. 
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Figure 42. Scatter plot of the effects of 1µM E804 on RAW 264.7 macrophage 
growth arrest and senescence related gene expression. Data represents the fold 
change in RFU between E804 and control treated cells. 
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Figure 43. Scatter plot of the effects of 1µM PCB-126 on RAW 264.7 
macrophage growth arrest and senescence related gene expression. Data 
represents the fold change in RFU between PCB-126 and control treated cells. 
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Figure 44. Scatter plot of the effects of 1µM Io + LPS on RAW 264.7 macrophage 
growth arrest and senescence related gene expression. Data represents the fold 
change in RFU between Io + LPS and LPS treated cells. 
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Figure 45. Scatter plot of the effects of 1µM E804 + LPS on RAW 264.7 
macrophage growth arrest and senescence related gene expression. Data 
represents the fold change in RFU between E804 + LPS and LPS treated cells. 
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Figure 46. Scatter plot of the effects of 1µM PCB-126 + LPS on RAW 264.7 
macrophage growth arrest and senescence related gene expression. Data 
represents the fold change in RFU between PCB-126 + LPS and LPS treated 
cells. 
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Figure 47. Scatter plot of the effects of LPS on RAW 264.7 macrophage 
apoptotic related gene expression. Data represents the fold change in RFU 
between LPS and control treated cells. 
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Figure 48. Scatter plot of the effects of 1µM Io on RAW 264.7 macrophage 
apoptotic related gene expression. Data represents the fold change in RFU 
between Io and control treated cells. 
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Figure 49. Scatter plot of the effects of 1µM E804 on RAW 264.7 macrophage 
apoptotic related gene expression. Data represents the fold change in RFU 
between E804 and control treated cells. 
INDUCED 
GENES 
SUPPRESSED 
GENES 
HOUSEKEEPING 
GENES 
Fasl 
Tnfsf10 
Casp1 
Anxa5 
Bcl2l1 
Nfkbi
 
Bax 
Tradd 
Tnfsf1a 
Casp8 
  113 
 
 
Figure 50. Scatter plot of the effects of 1µM PCB-126 on RAW 264.7 
macrophage apoptotic related gene expression. Data represents the fold change 
in RFU between PCB-126 and control treated cells. 
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Figure 51. Scatter plot of the effects of 1µM Io + LPS on RAW 264.7 macrophage 
apoptotic related gene expression. Data represents the fold change in RFU 
between Io + LPS and LPS treated cells. 
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Figure 52. Scatter plot of the effects of 1µM E804 + LPS on RAW 264.7 
macrophage apoptotic related gene expression. Data represents the fold change 
in RFU between E804 + LPS and LPS treated cells. 
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Figure 53. Scatter plot of the effects of 1µM PCB-126 + LPS on RAW 264.7 
macrophage apoptotic related gene expression. Data represents the fold change 
in RFU between PCB-126 + LPS and LPS treated cells. 
INDUCED GENES 
SUPPRESSED GENES 
HOUSEKEEPING 
GENES 
Bax Bcl121 
Tnfrsf1a 
 
Gapdh 
Actb 
Hsp90 
  117 
 
 
Figure 54. Scatter plot of the effects of LPS on RAW 264.7 macrophage stress 
related gene expression. Data represents the fold change in RFU between LPS 
and control treated cells. 
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Figure 55. Scatter plot of the effects of 1µM Io on RAW 264.7 macrophage stress 
related gene expression. Data represents the fold change in RFU between Io and 
control treated cells. 
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Figure 56. Scatter plot of the effects of 1µM E804 on RAW 264.7 macrophage 
stress related gene expression. Data represents the fold change in RFU between 
E804 and control treated cells. 
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Figure 57. Scatter plot of the effects of 1µM PCB-126 on RAW 264.7 
macrophage stress related gene expression. Data represents the fold change in 
RFU between PCB-126 and control treated cells. 
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Figure 58. Scatter plot of the effects of 1µM Io + LPS on RAW 264.7 macrophage 
stress related gene expression. Data represents the fold change in RFU between 
Io + LPS and LPS treated cells. 
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Figure 59. Scatter plot of the effects of 1µM E804 + LPS on RAW 264.7 
macrophage stress related gene expression. Data represents the fold change in 
RFU between E804 + LPS and LPS treated cells. 
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Figure 60. Scatter plot of the effects of 1µM PCB-126 + LPS on RAW 264.7 
macrophage stress related gene expression. Data represents the fold change in 
RFU between PCB-126 + LPS and LPS treated cells. 
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